Defective Drugs

12 Core Facts About GlaxoSmithKline’s Zofran And This Litigation

To learn more about Zofran, please read our previous articles: “Lawsuit Filed Against the Manufacturers of Zofran” and “Studies Link Zofran to Birth Defects.” Did you or a loved one take Zofran during pregnancy? Here are 12 core facts you should know about Zofran: 1. GlaxoSmithKline (GSK) manufactured Zofran (active ingredient: Ondansetron Hydrochloride). 2. In the […]

Type 2 Diabetes Drugs Linked to Adverse Effects

On May 15, 2015, the FDA issued a drug safety alert based on data linking the use of certain type-2 diabetes drugs (sodium-glucose-cotransporter-2 (SGLT-2) inhibitors) with ketoacidosis. Ketoacidosis is a serious medical condition, usually requiring hospitalization, in which one’s blood becomes overly saturated with acids known as ketones. Typical symptoms of the condition include nausea, […]

Actos: $2.4 Billion Settlement

Pope McGlamry – April 29, 2015 – After years of litigation, culminating in a $9 billion jury verdict, Takeda Pharmaceutical has agreed to pay $2.4 billion to settle 9,000 cases involving bladder cancer associated with the use of Actos. Takeda has not admitted liability, but is willing to resolve these cases to “reduce the uncertainties […]

Johnson & Johnson’s Janssen Pharmaceuticals Receives Mixed Verdict in Second Risperdal Trial

On Friday, March 20, 2014, a jury in Philadelphia found that Johnson & Johnson’s Janssen Pharmaceuticals failed to warn consumers that the antipsychotic drug Risperdal could cause male breast growth, but it awarded no damages finding causation of a direct link between the drug and the plaintiff’s condition was not conclusively proved. The case was […]

Takeda Ordered to Pay Over $2 Million to Actos Patient

Takeda Pharmaceutical Company, a major prescription drug manufacturer based in Osaka, Japan has recently been ordered to pay more than $2 million in compensation to a Pennsylvanian woman who claims that her bladder cancer was caused by Actos, a popular antidiabetic. A Philadelphia jury found that Takeda to have failed to warn the patient about […]

Hip Implant Systems Not Adequately Tested

Recently published research reveals that the Food and Drug Administration (FDA) has not done an adequate job at regulating hip replacement systems. As the first trials over Johnson & Johnson’s defective Pinnacle Ultamet hip implant equipment begin across the United States, patients and doctors are left wondering whether these manufacturers were asked to provide evidence […]

Blue Shield and Blue Cross File Claim Over Actos

In a recent addition to the ongoing Actos ordeal, Blue Shield and Blue Cross filed complaints against Takeda Pharmaceuticals on June 11, 2014. The two insurance providers are seeking compensation for payouts related to bladder cancer risk associated with Actos, a prescription drug for Type II diabetes patients. Takeda and their Indianapolis-based marketing partner, Eli […]

Jury Awards $9 Billion after an Actos Trial

Terrence Allen and his wife’s lawsuit alleged that Allen developed bladder cancer as a result of using Actos to treat diabetes between 2004 and 2011. Plaintiffs argued that Actos manufacturer Takeda failed to disclose the link between Actos and bladder cancer.

FDA Begins Regulating Apps

Everyone with a smartphone or tablet computer has likely run across one of the tens of thousands of health-related apps that can now be downloaded. Some of the apps work by tracking calories, exercise, monitoring blood pressure or blood sugar and others even exist to diagnose health conditions. Despite the seriousness of the apps, there […]